Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

Real-time Quote. Real-time Tradegate - 08/24 03:57:34 pm
73.075 EUR   +0.19%
08/19 UCB : Transparency notification
08/18 UCB : Transparency notification
08/14 UCB : U.S. District Court confirms validity of patent for UCB's Vimp..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Deutsche Boerse Ag
08/18/2016 08/19/2016 08/22/2016 08/23/2016 08/24/2016 Date
72.704(c) 72.448(c) 71.162(c) 72.935(c) 72.694 Last
0 0 0 0 0 Volume
-0.02% -0.35% -1.78% +2.49% -0.33% Change
More quotes
Financials (€)
Sales 2016 4 047 M
EBIT 2016 736 M
Net income 2016 465 M
Debt 2016 988 M
Yield 2016 1,73%
Sales 2017 4 298 M
EBIT 2017 896 M
Net income 2017 572 M
Debt 2017 656 M
Yield 2017 1,84%
P/E ratio 2016 28,37
P/E ratio 2017 22,93
EV / Sales2016 3,75x
EV / Sales2017 3,46x
Capitalization 14 199 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
10/25Earnings Release
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB SA
08/19 UCB : Transparency notification
08/18 UCB : Transparency notification
08/14 UCB : U.S. District Court confirms validity of patent for UCB's Vimpat®
08/05 AMPHASTAR PHARMACEUTICALS : Purchases International Medication Systems (UK) Limi..
07/28 UCB : continues to deliver on its growth strategy
07/25 AMGEN : UCB and Amgen submit biologics license application for Romosozumab to th..
07/05 DAIICHI SANKYO : UCB and Daiichi Sankyo will jointly commercialize lacosamide in..
07/04 UCB : and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VI..
06/10 UCB : bimekizumab demonstrates positive results in early development in patients..
06/08 UCB : commitment to addressing real world patient needs on display at the Annual..
More news
Sector news : Pharmaceuticals - NEC
11:34aDJPFIZER : Buys Part of AstraZeneca's Antibiotics Business -- 2nd Update
10:32aDJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
10:15aDJPfizer Buys Part of AstraZeneca's Antibiotics Business
09:48a ASTRAZENECA : Pfizer to buy antibiotics business from AstraZeneca
09:03aDJASTRAZENECA : Sells Part of Antibiotics Business to Pfizer for Up to $1.575 Bill..
More sector news : Pharmaceuticals - NEC
Advertisement
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 17
Average target price 78,8 €
Spread / Average Target 7,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB SA-14.61%16 029
JOHNSON & JOHNSON16.28%326 773
ROCHE HOLDING LTD.-12.26%219 257
NOVARTIS AG-9.97%214 603
PFIZER INC.8.71%212 844
MERCK & CO., INC.20.37%175 812
More Results